CONVENTION ON INTERNATIONAL TRADE IN ENDANGERED SPECIES OF WILD FAUNA AND FLORA



Nineteenth meeting of the Conference of the Parties Panama City (Panama), 14 – 25 November 2022

Committee I

Trade in medicinal and aromatic plant species

DRAFT DECISIONS OF THE CONFERENCE OF THE PARTIES

This document has been prepared by the drafting group on medicinal and aromatic plant species on the basis of document CoP19 Doc. 82 after discussion in the fourth session of Committee I (see document <u>CoP18 Com. I Rec. 4</u>).

Draft decisions on *Trade in medicinal and aromatic plant species*

Directed to the Secretariat

19.AA The Secretariat shall, in close collaboration with the Plants Committee:

- a) publish a notification inviting Parties to:
 - share information materials that have been developed to enhance awareness of CITES regulations and to encourage sustainable use and legal trade in CITES-listed medicinal and aromatic plants and, as far as possible, liaise with key stakeholders of medicinal and aromatic plant trade supply chains for this purpose,
 - ii) review their non-detriment findings (NDFs) for medicinal and aromatic plants and consider sharing such with the Secretariat to be included on the NDF section of the CITES website;
 - iii) assess the utility of the Medicinal Plant Names Service (MPNS) database in their routine work to see if it can contribute to the expansion of the Species+ database; and share any experience of using the MPNS database;
- b) make information materials for raising awareness of CITES regulations for the medicinal and aromatic plant industry stakeholders and consumers available to Parties on the CITES website;
- subject to external funding, undertake an analysis of e-commerce supply chains in products of CITESlisted medicinal and aromatic plant species, exploring the applicability of using the Medicinal Plant Names Service (MPNS) database in the analysis, and including
 - i) a stakeholder analysis of key producers, intermediate traders, manufacturers or distribution platforms to end consumers, and of institutions influencing the demand for CITES-regulated medicinal and aromatic plant products in biomedical, traditional and alternative medical systems, cosmetic and personal care, food industries (as appropriate), and

- ii) an assessment whether existing annotations are adequate with respect to the principles and principles recommended in Resolution Conf. 11.21 (Rev. CoP18) on *Use of Annotations in Appendices I and II*; and
- d) report to the Plants Committee on the implementation of this Decision, including suggestions, as appropriate, regarding Resolution Conf. 10.19 (Rev. CoP14) on *Traditional medicines* or a new Resolution in relation to medicinal and aromatic plant products.

Directed to Parties

19.BB Parties are invited to support the implementation of Decision 19.AA.

Directed to the Plants Committee

- **19.CC** The Plants Committee shall:
 - a) be informed and review the report of the Secretariat, and the feedback from Parties as per Decision 19.AA, regarding the utility of the Medicinal Plant Names Service, with advice from the nomenclature specialist, as appropriate;
 - b) taking into consideration the information in document PC25 Doc. 30, information document CoP18 Inf. 11, the report of the Secretariat as per Decision 19.AA, and other relevant information, and in consultation with the Animals Committee, as appropriate, undertake a review of Resolution Conf. 10.19 (Rev. CoP14) on *Traditional medicines*, and prepare recommendations for a revised Resolution on traditional medicines or a new Resolution on medicinal and aromatic plant products; and
 - c) submit its recommendations to the Standing Committee or the Conference of the Parties, as appropriate.

Directed to the Standing Committee

19.DD The Standing Committee shall review the report from the Plants Committee as per Decision 19.CC, as appropriate, and make recommendations, as appropriate, to the Conference of the Parties.